Shire PLC (NASDAQ:SHPG) – Equities research analysts at Cantor Fitzgerald issued their FY2017 earnings estimates for Shire PLC in a research report issued to clients and investors on Monday. Cantor Fitzgerald analyst L. Chen expects that the biopharmaceutical company will earn $14.41 per share for the year. Cantor Fitzgerald has a “Buy” rating and a $222.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Shire PLC’s FY2018 earnings at $15.24 EPS.
SHPG has been the topic of several other reports. Sanford C. Bernstein lowered shares of Shire PLC from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $209.22 to $161.09 in a report on Thursday, May 25th. HSBC Holdings plc lowered shares of Shire PLC from a “hold” rating to a “reduce” rating in a report on Friday, May 19th. Goldman Sachs Group, Inc. (The) increased their target price on shares of Shire PLC from $202.00 to $214.00 and gave the stock an “overweight” rating in a report on Monday, April 17th. Jefferies Group LLC set a $239.00 target price on shares of Shire PLC and gave the stock a “buy” rating in a report on Thursday, April 20th. Finally, Royal Bank Of Canada reiterated a “buy” rating and issued a $221.00 target price on shares of Shire PLC in a report on Tuesday, March 14th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $223.01.
TRADEMARK VIOLATION WARNING: This piece was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/07/31/equities-analysts-set-expectations-for-shire-plcs-fy2017-earnings-nasdaqshpg-updated-updated-updated.html.
Shares of Shire PLC (NASDAQ SHPG) opened at 169.33 on Thursday. Shire PLC has a 52 week low of $161.09 and a 52 week high of $209.22.
Shire PLC (NASDAQ:SHPG) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.22 by $0.41. Shire PLC had a net margin of 2.14% and a return on equity of 13.05%. The company had revenue of $3.57 billion for the quarter. During the same period last year, the firm earned $2.12 earnings per share. Shire PLC’s revenue for the quarter was up 109.0% compared to the same quarter last year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SHPG. Dumont & Blake Investment Advisors LLC increased its position in Shire PLC by 0.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 2,594 shares of the biopharmaceutical company’s stock worth $452,000 after buying an additional 7 shares during the period. Level Four Advisory Services LLC increased its position in Shire PLC by 0.5% in the first quarter. Level Four Advisory Services LLC now owns 2,745 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 13 shares during the period. Thompson Davis & CO. Inc. increased its position in Shire PLC by 3.1% in the first quarter. Thompson Davis & CO. Inc. now owns 640 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 19 shares during the period. Macquarie Group Ltd. increased its position in Shire PLC by 2.2% in the fourth quarter. Macquarie Group Ltd. now owns 1,417 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 31 shares during the period. Finally, American International Group Inc. increased its position in Shire PLC by 1.2% in the first quarter. American International Group Inc. now owns 4,607 shares of the biopharmaceutical company’s stock worth $803,000 after buying an additional 54 shares during the period. 20.93% of the stock is owned by institutional investors and hedge funds.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Shire PLC and related companies with MarketBeat.com’s FREE daily email newsletter.